Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
About this item
Full title
Author / Creator
Scholler, Nathalie , Perbost, Regis , Locke, Frederick L. , Jain, Michael D. , Turcan, Sarah , Danan, Corinne , Chang, Edmund C. , Neelapu, Sattva S. , Miklos, David B. , Jacobson, Caron A. , Lekakis, Lazaros J. , Lin, Yi , Ghobadi, Armin , Kim, Jenny J. , Chou, Justin , Plaks, Vicki , Wang, Zixing , Xue, Allen , Mattie, Mike , Rossi, John M. , Bot, Adrian and Galon, Jérôme
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-ce...
Alternative Titles
Full title
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Authors, Artists and Contributors
Author / Creator
Perbost, Regis
Locke, Frederick L.
Jain, Michael D.
Turcan, Sarah
Danan, Corinne
Chang, Edmund C.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Kim, Jenny J.
Chou, Justin
Plaks, Vicki
Wang, Zixing
Xue, Allen
Mattie, Mike
Rossi, John M.
Bot, Adrian
Galon, Jérôme
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9499856
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9499856
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-022-01916-x
